Literature DB >> 30361780

Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).

Peng Zhu1, Zhi Ye2,3, Dong Guo2,4, Zongping Xiong1, Shiqiong Huang1, Jun Guo1, Wei Zhang1, James E Polli2, Honghao Zhou1, Qing Li5,6, Yan Shu7,8,9.   

Abstract

PURPOSE: The organic cation transporters (OCTs) and multidrug and toxin extrusions (MATEs) together are regarded as an organic cation transport system critical to the disposition and response of many organic cationic drugs. Patient response to the analgesic morphine, a characterized substrate for human OCT1, is highly variable. This study was aimed to examine whether there is any organic cation transporter-mediated drug and drug interaction (DDI) between morphine and commonly co-administrated drugs.
METHODS: The uptake of morphine and its inhibition by six drugs which are commonly co-administered with morphine in the clinic were assessed in human embryonic kidney 293 (HEK293) cells stably expressing OCT1, OCT2 and MATE1. The in vivo interaction between morphine and the select irinotecan was determined by comparing the disposition of morphine in the absence versus presence of irinotecan treatment in mice.
RESULTS: The uptake of morphine in the stable HEK293 cells expressing human OCT1 and OCT2 was significantly increased by 3.56 and 3.04 fold, respectively, than that in the control cells, with no significant uptake increase in the cells expressing human MATE1. All of the six drugs examined, including amitriptyline, fluoxetine, imipramine, irinotecan, ondansetron, and verapamil, were inhibitors of OCT1/2-mediated morphine uptake. The select irinotecan significantly increased the plasma concentrations and decreased hepatic and renal accumulation of morphine in mice.
CONCLUSIONS: Morphine is a substrate of OCT1 and OCT2. Clinician should be aware that the disposition of and thus the response to morphine may be altered by co-administration of an OCT1/2 inhibitor, such as irinotecan.

Entities:  

Keywords:  drug and drug interactions; irinotecan; morphine; organic cation transporters

Mesh:

Substances:

Year:  2018        PMID: 30361780      PMCID: PMC6294118          DOI: 10.1007/s11095-018-2526-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  46 in total

1.  The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Authors:  M V Tzvetkov; S V Vormfelde; D Balen; I Meineke; T Schmidt; D Sehrt; I Sabolić; H Koepsell; J Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2009-06-17       Impact factor: 6.875

2.  Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1).

Authors:  Qing Li; Zhi Ye; Peng Zhu; Dong Guo; Hong Yang; Jin Huang; Wei Zhang; James E Polli; Yan Shu
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

Review 3.  Role of organic cation transporters in drug-drug interaction.

Authors:  Hermann Koepsell
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-24       Impact factor: 4.481

4.  Opioid dose and drug-related mortality in patients with nonmalignant pain.

Authors:  Tara Gomes; Muhammad M Mamdani; Irfan A Dhalla; J Michael Paterson; David N Juurlink
Journal:  Arch Intern Med       Date:  2011-04-11

Review 5.  Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine.

Authors:  Anne T Nies; Katja Damme; Stephan Kruck; Elke Schaeffeler; Matthias Schwab
Journal:  Arch Toxicol       Date:  2016-05-10       Impact factor: 5.153

6.  Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.

Authors:  Aditi Mulgaonkar; Jürgen Venitz; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

Review 7.  Oral morphine for cancer pain.

Authors:  Philip J Wiffen; Bee Wee; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2013-07-22

Review 8.  Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.

Authors:  Anne T Nies; Hermann Koepsell; Katja Damme; Matthias Schwab
Journal:  Handb Exp Pharmacol       Date:  2011

9.  Genetic variants of the organic cation transporter 2 influence the disposition of metformin.

Authors:  I S Song; H J Shin; E J Shim; I S Jung; W Y Kim; J H Shon; J G Shin
Journal:  Clin Pharmacol Ther       Date:  2008-04-09       Impact factor: 6.875

Review 10.  Relationships among morphine metabolism, pain and side effects during long-term treatment: an update.

Authors:  Gertrud Andersen; Lona Christrup; Per Sjøgren
Journal:  J Pain Symptom Manage       Date:  2003-01       Impact factor: 3.612

View more
  8 in total

Review 1.  Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models.

Authors:  Bastian Haberkorn; Martin F Fromm; Jörg König
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

2.  Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.

Authors:  Noora Sjöstedt; Sibylle Neuhoff; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2020-11-06       Impact factor: 6.875

3.  A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators.

Authors:  Yiting Yang; Zexin Zhang; Ping Li; Weimin Kong; Xiaodong Liu; Li Liu
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

4.  Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.

Authors:  Johannes Matthaei; Jürgen Brockmöller; Werner Steimer; Konstanze Pischa; Stefan Leucht; Maria Kullmann; Ole Jensen; Typhaine Ouethy; Mladen Vassilev Tzvetkov; Muhammad Rafehi
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

5.  In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs.

Authors:  Blessy George; Xia Wen; Edgar A Jaimes; Melanie S Joy; Lauren M Aleksunes
Journal:  Int J Mol Sci       Date:  2021-06-16       Impact factor: 6.208

6.  Bridging the gap between in silico and in vivo by modeling opioid disposition in a kidney proximal tubule microphysiological system.

Authors:  Tomoki Imaoka; Weize Huang; Sara Shum; Dale W Hailey; Shih-Yu Chang; Alenka Chapron; Catherine K Yeung; Jonathan Himmelfarb; Nina Isoherranen; Edward J Kelly
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

7.  Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota.

Authors:  Guilherme S Lopes; Jaime L Lopes; Suzette J Bielinski; Sebastian M Armasu; Ye Zhu; Dana C Cavanaugh; Ann M Moyer; Debra J Jacobson; Liwei Wang; Ruoxiang Jiang; Jennifer L St Sauver; Nicholas B Larson
Journal:  Pharmacogenomics J       Date:  2022-01-31       Impact factor: 3.245

8.  Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study.

Authors:  Ida Kuhlmann; Amanda Nøddebo Nyrup; Tore Bjerregaard Stage; Mette Marie Hougaard Christensen; Troels Korshøj Bergmann; Per Damkier; Flemming Nielsen; Kurt Højlund; Kim Brøsen
Journal:  Clin Transl Sci       Date:  2021-08-12       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.